Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

BGNE - BeiGene Ltd - ADR

IEX Last Trade
191.6
-6.900   -3.601%

Share volume: 293,387
Last Updated: Fri 30 Aug 2024 09:59:58 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%
$198.50
-6.90
-3.48%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
22%
Profitability 25%
Dept financing 9%
Liquidity 52%
Performance 16%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-1.05%
1 Month
22.17%
3 Months
24.33%
6 Months
7.45%
1 Year
-9.20%
2 Year
15.86%
Key data
Stock price
$191.60
P/E Ratio 
-35.53
DAY RANGE
N/A - N/A
EPS 
-$5.01
52 WEEK RANGE
$126.97 - $213.83
52 WEEK CHANGE
-$0.08
MARKET CAP 
18.607 B
YIELD 
N/A
SHARES OUTSTANDING 
97.023 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
BETA 
0.99
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$256,857
AVERAGE 30 VOLUME 
$323,352
Company detail
CEO: John Oyler
Region: US
Website: http://www.beigene.com/
Employees: 5,300
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib.

Recent news